IOVA vs JANX: fair value comparison
Iovance Biotherapeutics, Inc. and Janux Therapeutics, Inc. · Updated 2026-10-19
IOVA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. JANX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, IOVA currently ranks higher by quality score.
| IOVA | JANX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $13.62 | $16.51 |
| 12-month range | $1.81–$14.82 | $12.18–$34.74 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #103 of 301 Healthcare | #104 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | — | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: IOVA fair value analysis · JANX fair value analysis